Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping

This study evaluated over 200 RTCs of systemic therapy for NSCLC.  There has been a steady increase in the number of trials reporting outcomes for progression-free survival.  Over 50% of trials now report a positive outcome without meeting the primary endpoint of the trial.  Although the sample size of the trials is increasing, the magnitude of reported survival gain is decreasing (now 2.5 mos).